Help us make your voice heard: Myeloma UK launch COVID-19 survey

Myeloma UK news // 20th May 2020

What is it like to live with shielding?

How has the COVID- 19 pandemic affected your myeloma treatment and care?

What support do you and those close to you need now and in the future?

At Myeloma UK we know from the calls and emails we receive every day that COVID-19 is having a major impact on the lives of myeloma patients, their families and carers.

We want to know more about how you are being affected, and what is most important to you during this time, so we can make sure we are asking the right questions on your behalf and that your voice counts with decision makers.

That is why we have launched a survey to help us better understand how COVID-19 is impacting everyone with a diagnosis of myeloma or a related condition.

We believe the impact of COVID-19 will be felt by myeloma patients for some time to come, so this is the first in a series of surveys which will give us valuable insight into how COVID-19 is affecting myeloma patients’ lives now and into the future.

Speaking about the survey launch, Sarah McDonald, Director of Research, Myeloma UK said:

“ This is one of the most comprehensive and important pieces of work we have ever done: The more responses we have, the better we understand what patients need, and the stronger our case will be as we push for increased support from the NHS and UK Government.

Myeloma patients have many things in common, but they are also individuals. We want to better understand how COVID- 19 is affecting myeloma patients, depending on their individual circumstances.

At Myeloma UK we have 21 years of experience in working exclusively for patients with myeloma and related conditions and we are in a unique position to tell the story of COVID – 19 from your perspective. You can help us achieve that goal by completing the survey and sharing with others within the myeloma community.”

The survey can be accessed here

If you have any further queries regarding the survey please contact us at: